Guidance
Pneumococcal Vaccine: Handling the change in product manufacturer and presentation
Summary guidance for national authorities and immunization programme managers for the switch from GlaxoSmithKline Biologicals SA Synflorix® (PCV 10) to Pfizer Prevenar13® vaccine (PCV 13)
Authors
Languages
- Portuguese
Publication year
2017
Publisher
World Health Organization
Type
Guidance
Categories
- Vaccines & delivery devices
Diseases
- Pneumococcal disease
Topic references
EPI-CORE-PNEUMO
| Title | Author | Year | Type | Language |
|---|---|---|---|---|
| Characteristics of different presentations of Pneumococcal Conjugate Vaccines | World Health Organization (WHO) | 2017 | Poster/infographic | English |
| Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs) | Gavi, the Vaccine Alliance | 2017 | Guidance | English |
| Pneumococcal Vaccine: Handling the change in product manufacturer and presentation | World Health Organization (WHO) | 2017 | Guidance | Portuguese |
